{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:21:28Z","timestamp":1794896488489,"version":"4.9.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00210-026-05673-3","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:10:42Z","timestamp":1783138242000},"page":"21695-21699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A successful switch from rasagiline to safinamide in a 49-year-old female with early-onset Parkinson\u2019s disease: a case report and review of literature"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-3390","authenticated-orcid":false,"given":"Shiloh","family":"Plaut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Carmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Barash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"11","key":"5673_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/01616412.2021.1942408","volume":"43","author":"E Bianchini","year":"2021","unstructured":"Bianchini E, Sforza M, Rinaldi D, Alborghetti M, De Carolis L, Della Gatta F, Pontieri FE (2021) Switch from rasagiline to safinamide in fluctuating Parkinson\u2019s disease patients: a retrospective, pilot study. Neurol Res 43(11):950\u2013954. https:\/\/doi.org\/10.1080\/01616412.2021.1942408","journal-title":"Neurol Res"},{"issue":"7","key":"5673_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-021-00832-x","volume":"35","author":"SR Chamberlain","year":"2021","unstructured":"Chamberlain SR, Baldwin DS (2021) Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively. CNS Drugs 35(7):703\u2013716. https:\/\/doi.org\/10.1007\/s40263-021-00832-x","journal-title":"CNS Drugs"},{"key":"5673_CR3","first-page":"622","volume":"42","author":"MP Cruz","year":"2017","unstructured":"Cruz MP (2017) Xadago (Safinamide): a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson\u2019s disease. Pharm Ther 42:622\u2013637","journal-title":"Pharm Ther"},{"issue":"11","key":"5673_CR4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00702-018-1932-y","volume":"125","author":"PK Gillman","year":"2018","unstructured":"Gillman PK (2018) A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna) 125(11):1707\u20131717. https:\/\/doi.org\/10.1007\/s00702-018-1932-y","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"5673_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"G H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger G, German Parkinson\u2019s Guidelines Committee, Trenkwalder C (2024) Diagnosis and treatment of Parkinson\u2019s disease (guideline of the German Society for Neurology). Neurol Res Pract 6(1):30. https:\/\/doi.org\/10.1186\/s42466-024-00325-4","journal-title":"Neurol Res Pract"},{"issue":"10","key":"5673_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/brainsci9100272","volume":"9","author":"G Mart\u00ed-Andr\u00e9s","year":"2019","unstructured":"Mart\u00ed-Andr\u00e9s G, Jim\u00e9nez-Bola\u00f1os R, Arbelo-Gonz\u00e1lez JM, Pagonabarraga J, Duran-Herrera C, Valenti-Azcarate R, Luquin MR (2019) Safinamide in clinical practice: a Spanish multicenter cohort study. Brain Sci 9(10):272. https:\/\/doi.org\/10.3390\/brainsci9100272","journal-title":"Brain Sci"},{"issue":"5","key":"5673_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","volume":"120","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Hoffmann JA, Dimpfel W, Oehlwein C (2013) Switch from selegiline to rasagiline is beneficial in patients with Parkinson\u2019s disease. J Neural Transm (Vienna) 120(5):761\u2013765. https:\/\/doi.org\/10.1007\/s00702-012-0927-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"5673_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/brainsci10030176","volume":"10","author":"J Pagonabarraga","year":"2020","unstructured":"Pagonabarraga J, Arbelo JM, Grandas F, Luquin MR, Mart\u00ednez Mart\u00edn P, Rodr\u00edguez-Oroz MC, Valldeoriola F, Kulisevsky J (2020) A Spanish consensus on the use of safinamide for Parkinson\u2019s disease in clinical practice. Brain Sci 10(3):176. https:\/\/doi.org\/10.3390\/brainsci10030176","journal-title":"Brain Sci"},{"issue":"2","key":"5673_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/brainsci13020276","volume":"13","author":"P Sanchez Alonso","year":"2023","unstructured":"Sanchez Alonso P, De La Casa-Fages B, Alonso-C\u00e1novas A, Mart\u00ednez-Castrillo JC (2023) Switching from rasagiline to safinamide as an add-on therapy regimen in patients with levodopa: a literature review. Brain Sci 13(2):276. https:\/\/doi.org\/10.3390\/brainsci13020276","journal-title":"Brain Sci"},{"key":"5673_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajem.2022.08.030","volume":"61","author":"A Spadaro","year":"2022","unstructured":"Spadaro A, Scott KR, Koyfman A, Long B (2022) High risk and low prevalence diseases: serotonin syndrome. Am J Emerg Med 61:90\u201397. https:\/\/doi.org\/10.1016\/j.ajem.2022.08.030","journal-title":"Am J Emerg Med"},{"issue":"1","key":"5673_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/ene.14552","volume":"28","author":"F Stocchi","year":"2021","unstructured":"Stocchi F, Vacca L, Grassini P, Tomino C, Caminiti G, Casali M, D\u2019Antoni V, Volterrani M, Torti M (2021) Overnight switch from rasagiline to safinamide in Parkinson\u2019s disease patients with motor fluctuations: a tolerability and safety study. Eur J Neurol 28(1):349\u2013354. https:\/\/doi.org\/10.1111\/ene.14552","journal-title":"Eur J Neurol"},{"issue":"2","key":"5673_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JPD-212976","volume":"12","author":"YY Tan","year":"2022","unstructured":"Tan YY, Jenner P, Chen SD (2022) Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future. J Parkinsons Dis 12(2):477\u2013493","journal-title":"J Parkinsons Dis"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05673-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:12:42Z","timestamp":1794895962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":12,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5673"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05673-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient provided written informed consent for publication of this case report. Institutional Review Board\/Ethics Committee review was not required because this manuscript describes a retrospective case report of a single patient and does not constitute human subjects research under institutional guidelines.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LLM ChatGPT 3.0\/3.5 and Gemini 2.5\/3.0 were used for grammar and language improvement. Generative AI was not used to generate scientific content, interpret data, formulate conclusions, or perform literature review.","order":4,"name":"Ethics","label":"Declaration of generative AI","group":{"name":"EthicsHeading","label":"Declarations"}}]}}